Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Grand Rapids, Michigan

Phase 1 cancer trials in Grand Rapids, MI

72 Phase 1 cancer studies are recruiting participants at sites in Grand Rapids as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Grand Rapids at a glance

  • 72 studies are recruiting at a site in Grand Rapids.
  • By phase: Early Phase 1 (1), Phase 1 (44), Phase 1/2 (27).
  • By sponsor: industry (68), university, hospital or other (4).
  • By research area: Breast Cancer (28), Lung Cancer (20), Prostate Cancer (10), Lymphoma (9), Melanoma (3), Pancreatic Cancer (2).
  • Most recent update to one of these records: November 17, 2026.

Breast cancer studies recruiting in Grand Rapids

Basic details from each study's public record (the 30 most recently updated of 72). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    START - Midwest Cancer Research Center
    Registry record
    NCT06253871 · updated
  2. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Aktis Oncology, Inc.
    Study site
    BAMF Health
    Registry record
    NCT07020117 · updated
  3. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    START Midwest
    Registry record
    NCT07488676 · updated
  4. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study site
    South Texas Accelerated Research Therapeutics (START)
    Registry record
    NCT06270706 · updated
  5. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    START Midwest - Oncology
    Registry record
    NCT06638307 · updated
  6. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    START Midwest, LLC
    Registry record
    NCT06827236 · updated
  7. Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Immunomic Therapeutics, Inc.
    Study site
    START Midwest
    Registry record
    NCT07652242 · updated
  8. A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    South Texas Accelerated Research Therapeutics (START) Midwest
    Registry record
    NCT07029399 · updated
  9. A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    START Midwest, LLC
    Registry record
    NCT07318805 · updated
  10. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    START Midwest
    Registry record
    NCT05579366 · updated
  11. A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    South Texas Accelerated Research Therapeutics (START) Midwest
    Registry record
    NCT06400472 · updated
  12. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    START Midwest Cancer and Hematology Centers of W Michigan
    Registry record
    NCT06465069 · updated
  13. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    BAMF Health Inc.
    Registry record
    NCT07114601 · updated
  14. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    BAMF Health Inc.
    Registry record
    NCT07213791 · updated
  15. A Study of MGC026 in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    MacroGenics
    Study site
    START Midwest
    Registry record
    NCT06242470 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Lung cancer studies recruiting in Grand Rapids

  1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    South Texas Accelerated Research Therapeutics (START) Midwest
    Registry record
    NCT05786924 · updated
  2. A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    START Midwest, LLC
    Registry record
    NCT07903415 · updated
  3. A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    START | Midwest
    Registry record
    NCT06914128 · updated
  4. A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    START Midwest
    Registry record
    NCT06720987 · updated
  5. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Inc
    Study site
    START Midwest
    Registry record
    NCT07094204 · updated
  6. DBC-664 in Adult Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Duboce Biopharmaceuticals, Inc.
    Study site
    START Midwest
    Registry record
    NCT07705035 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Prostate cancer studies recruiting in Grand Rapids

  1. First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT07332455 · updated
  2. JUR-003 in Adult Patients With Metastatic Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Juri Biosciences, Inc.
    Study site
    START Midwest
    Registry record
    NCT07824349 · updated
  3. A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Start Midwest
    Registry record
    NCT05818683 · updated
  4. Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    South Texas Accelerated Research Therapeutics, LLC (START)
    Registry record
    NCT06800313 · updated
  5. A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Start Midwest
    Registry record
    NCT07746713 · updated
  6. A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Aktis Oncology, Inc.
    Study site
    BAMF Health
    Registry record
    NCT07581184 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Melanoma studies recruiting in Grand Rapids

  1. A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    START Midwest, LLC
    Registry record
    NCT07584226 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Lymphoma studies recruiting in Grand Rapids

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
    Registry record
    NCT04726241 · updated
  2. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    • Phase 1/2
    • From 6 months, up to 25 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Corewell Health ( Site 1001)
    Registry record
    NCT06395103 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Ask about studies near Grand Rapids

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Michigan

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call